Adding radiation to targeted therapy and immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether adding radiation therapy to a combination of targeted therapy and immunotherapy helps people with advanced liver cancer live longer and feel better. It reviews records from patients treated at Zhongshan Hospital to compare outcomes with and without radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hepatocellular carcinoma (the most common type of liver cancer).
- You received both targeted therapy and immunotherapy for your liver cancer at Zhongshan Hospital between January 2017 and December 2023.
- Your cancer is advanced (stage IIIa or IIIb), or is stage IIb and not suitable for surgery or TACE, or has a tumor clot in a major liver blood vessel, or has grown after other local treatments.
- You have not been told that radiation therapy is unsafe for you due to widespread liver tumors, poor overall health, severe liver dysfunction, or other serious medical issues.
- You have not had any other cancer (except treated early-stage cancers like cervical or skin cancer) in the past 5 years.
- You are willing to allow your biological samples and medical information to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This study looks at how adding local treatments (like targeted radiation or chemotherapy directly to the liver tumor) to your current immunotherapy and targeted therapy combination might affect outcomes for people with advanced liver cancer. It aims to find out which patients benefit most from adding these extra treatments.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.